There are 444 resources available
Invited Discussant LBA2 and 194MO
Presenter: Gerard Hanna
Session: Mini Oral session 1
Resources:
Slides
Webcast
Polypharmacy and concomitant medications as prognostic factors for immune checkpoint blockade
Presenter: Alessio Cortellini
Session: Optimising treatment for special populations
Resources:
Slides
Webcast
Cytokines and other immune modulators
Presenter: Paola Nisticò
Session: Overcoming IO resistance
Resources:
Slides
Webcast
Personalised cancer vaccine and cell therapy
Presenter: Mark Awad
Session: Overcoming IO resistance
Resources:
Slides
Webcast
Q&A
Session: Mini Oral session 1
Resources:
Webcast
1MO - A phase IIIb study of savolitinib in patients with locally advanced or metastatic NSCLC harboring MET exon 14 mutation
Presenter: yongchang zhang
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
Exercise in lung cancer: Time to get moving
Presenter: Morten Quist
Session: Optimising treatment for special populations
Resources:
Slides
Webcast
Q&A and discussion
Session: Overcoming IO resistance
Resources:
Webcast
137MO - Phase II study of becotarug (JMT101) combined with osimertinib in patients (pts) with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion (ex20ins) mutations (BECOME study)
Presenter: Zhang Li
Session: Mini Oral session 1
Resources:
Abstract
Q&A and discussion
Session: Optimising treatment for special populations
Resources:
Webcast